Should You Buy AstraZeneca plc Instead Of Hikma Pharmaceuticals Plc, BTG plc And GW Pharmaceuticals plc?

Is there better opportunity to make a profit with AstraZeneca plc (LON: AZN) or sector peers Hikma Pharmaceuticals Plc (LON: HIK), BTG plc (LON: BTG) and GW Pharmaceuticals plc (LON: GWP)?

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

When investing, your capital is at risk. The value of your investments can go down as well as up and you may get back less than you put in.

Read More

The content of this article is provided for information purposes only and is not intended to be, nor does it constitute, any form of personal advice. Investments in a currency other than sterling are exposed to currency exchange risk. Currency exchange rates are constantly changing, which may affect the value of the investment in sterling terms. You could lose money in sterling even if the stock price rises in the currency of origin. Stocks listed on overseas exchanges may be subject to additional dealing and exchange rate charges, and may have other tax implications, and may not provide the same, or any, regulatory protection as in the UK.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

2015 has been a rather mixed year thus far for the pharmaceutical sector. That’s because, while the likes of AstraZeneca (LSE: AZN) (NYSE: AZN.US) and BTG (LSE: BTG) have seen their share prices fall by 1.5% and 1% respectively, superb gains have been on offer elsewhere in the sector. For example, Hikma (LSE: HIK) and GW (LSE: GW) have seen their share prices soar by 27% and 26% since the turn of the year.

Looking ahead, though, which of the four is the best buy for longer-term investors?

Valuations

Clearly, pharmaceutical stocks tend to trade at a premium to the wider index, so comparing them directly to the FTSE 100, for example, is unlikely to lead to a conclusion that they offer good value for money. Of course, they tend to trade on premium valuations because of their appealing mix of defensive characteristics and strong growth potential, so even though AstraZeneca has a price to earnings (P/E) ratio of 16.3 (which is higher than the FTSE 100’s P/E ratio of around 16), it still seems to offer good relative value for money.

Should you invest £1,000 in Anglo American right now?

When investing expert Mark Rogers has a stock tip, it can pay to listen. After all, the flagship Motley Fool Share Advisor newsletter he has run for nearly a decade has provided thousands of paying members with top stock recommendations from the UK and US markets. And right now, Mark thinks there are 6 standout stocks that investors should consider buying. Want to see if Anglo American made the list?

See the 6 stocks

That’s because Hikma, BTG and GW have P/E ratios of 26.2, 37.7 and, in the case, of GW, its status as a loss-making company means it does not have a positive P/E ratio. As such, AstraZeneca is certainly the cheapest of the four stocks but, as mentioned, future growth potential can be significant in the pharmaceutical sector.

Growth Prospects

There is a clear split when it comes to the growth forecasts of the four companies over the next couple of years. That’s because, while AstraZeneca’s bottom line is expected to decline in the low-single digits before resuming growth in 2017, and GW’s losses are due to widen in 2015 and 2016, BTG and Hikma have relatively bright futures.

For example, Hikma’s bottom line is forecast to grow by 6% this year and by 15% next year, which puts it on a relatively appealing price to earnings growth (PEG) ratio of 1.6. However, BTG seems to have much greater appeal despite its higher P/E ratio, with it set to post earnings growth of 27% and 53% over the next two years, which puts it on a PEG ratio of just 0.5.

Looking Ahead

Although AstraZeneca is going through a challenging period, with its loss of patents continuing to impact on its bottom line, it still offers excellent value for money relative to its sector peers. Certainly, BTG has considerable appeal, with its stunning prospects meaning that it appears to offer growth at a very reasonable price and could be worth buying at the present time.

Furthermore, Hikma also has great potential to continue its run thus far in 2015, although GW’s forecast increase in losses could cause its share price to come under pressure in the medium term, with investors having other strong options within the pharmaceuticals space available to them.

However, while there is opportunity elsewhere, AstraZeneca still seems to be the pick of the four companies due to its long-term potential and appealing valuation. And, for long term, patient investors, it could deliver stunning share price growth as its acquisition spree is all set to revitalise its top and bottom lines.

But there are other promising opportunities in the stock market right now. In fact, here are:

5 stocks for trying to build wealth after 50

The cost of living crisis shows no signs of slowing… the conflict in the Middle East and Ukraine shows no sign of resolution, while the global economy could be teetering on the brink of recession.

Whether you’re a newbie investor or a seasoned pro, deciding which stocks to add to your shopping list can be a daunting prospect during such unprecedented times. Yet despite the stock market’s recent gains, we think many shares still trade at a discount to their true value.

Fortunately, The Motley Fool UK analyst team have short-listed five companies that they believe STILL boast significant long-term growth prospects despite the global upheaval…

We’re sharing the names in a special FREE investing report that you can download today. We believe these stocks could be a great fit for any well-diversified portfolio with the goal of building wealth in your 50’s.

Claim your free copy now

Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice.

Peter Stephens owns shares of AstraZeneca. The Motley Fool UK has recommended BTG. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

Investing Articles

Nvidia stock is down 24% this year. Time to buy the dip?

Christopher Ruane has been eyeing Nvidia stock as a potential addition to his portfolio for a while. Is a recent…

Read more »

Petrochemical engineer working at night with digital tablet inside oil and gas refinery plant
Investing Articles

Down 25% since January, this resilient dividend stock’s catching my eye

Maintaining the UK’s rail, water, and energy infrastructure isn’t the most exciting business. But it has made this a solid…

Read more »

Investing Articles

Prediction: Unilever to outperform the FTSE 100 over the next 12 months

The FTSE 100 has made a strong start to 2025, but Stephen Wright thinks a popular dividend stock could be…

Read more »

Investing Articles

I just bought this legendary S&P 500 tech stock for my ISA, 27% off its highs

This S&P 500 stock has tanked over the last month and Edward Sheldon has snapped it up for his portfolio…

Read more »

Young black man looking at phone while on the London Overground
Investing Articles

2 beaten-down stocks to consider for an ISA after the massive market sell-off!

The stock market has had a sudden meltdown! Yet our writer thinks these two growth stocks look attractive candidates for…

Read more »

British Pennies on a Pound Note
Investing Articles

I asked ChatGPT what the best UK penny stock was. This is what it said…

Can AI find winning penny stock investments? Zaven Boyrazian puts ChatGPT to the test and discovers a potentially interesting opportunity.

Read more »

Investing Articles

These FTSE 100 stocks could be the winners from Trump’s tariffs!

President Trump’s unpopular tariffs caused mayhem on the world’s stock markets this week. But some FTSE 100 stocks bucked this…

Read more »

Investing Articles

Are these 3 sold-off UK shares secretly screaming buys?

Despite the FTSE 100 rising, there are still plenty of struggling UK shares. But are these three sold-off stocks potential…

Read more »